Michael G. Grey's Insider Trades & SAST Disclosures
Michael G. Grey's most recent trade in Mirum Pharmaceuticals Inc was a trade of 102,788 Common Stock done . Disclosure was reported to the exchange on Sept. 27, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Michael G. Grey.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 27 Sep 2024 | 102,788 | 186,410 (0%) | 0% | 0 | Common Stock | |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 8,779 | 8,779 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 5,703 | 5,703 | - | - | Deferred Stock Units | |
| Spruce Biosciences Inc | Michael G. Grey | Director, Executive Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2023 | 14,216 | 331,176 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 13 Sep 2023 | 14,216 | 14,216 (0%) | 0% | 2.9 | 41,738 | Common Stock |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 13 Sep 2023 | 14,216 | 0 (0%) | 0% | 32 | 454,912 | Common Stock |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Sep 2023 | 392 | 345,392 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 13 Sep 2023 | 392 | 392 (0%) | 0% | 2.9 | 1,151 | Common Stock |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 32.00 per share. | 13 Sep 2023 | 392 | 0 (0%) | 0% | 32 | 12,544 | Common Stock |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2023 | 17,000 | 17,000 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 08 Jun 2023 | 14,608 | 14,608 (0%) | 0% | 2.9 | 42,889 | Common Stock |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 29.00 per share. | 08 Jun 2023 | 14,608 | 0 (0%) | 0% | 29 | 423,632 | Common Stock |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jun 2023 | 14,608 | 345,784 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2023 | 14,608 | 360,392 | - | - | Stock Option (right to buy) | |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.94 per share. | 03 May 2023 | 14,608 | 14,608 (0%) | 0% | 2.9 | 42,889 | Common Stock |
| Mirum Pharmaceuticals Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 28.00 per share. | 03 May 2023 | 14,608 | 0 (0%) | 0% | 28 | 409,024 | Common Stock |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 3,913 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2023 | 3,913 | 19,361 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 4,223 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Apr 2022 | 4,223 | 66,513 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2022 | 3,913 | 3,913 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 98.56 per share. | 28 Apr 2022 | 1,139 | 65,374 (0%) | 0% | 98.6 | 112,260 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2021 | 5,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.37 per share. | 22 Jul 2021 | 5,000 | 5,000 (0%) | 0% | 2.4 | 11,850 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 100.05 per share. | 22 Jul 2021 | 4,000 | 0 (0%) | 0% | 100.1 | 400,200 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 22 Jul 2021 | 1,000 | 4,000 (0%) | 0% | 100 | 100,000 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 11,098 | 73,388 (0%) | 0% | - | Ordinary Shares | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 11,098 | 0 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Apr 2021 | 4,223 | 4,223 | - | - | Restricted Stock Units | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.62 per share. | 29 Apr 2021 | 2,993 | 70,395 (0%) | 0% | 94.6 | 283,198 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Apr 2021 | 15,000 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 90.28 per share. | 12 Apr 2021 | 15,000 | 0 (0%) | 0% | 90.3 | 1,354,200 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.37 per share. | 12 Apr 2021 | 15,000 | 15,000 (0%) | 0% | 2.4 | 35,550 | Ordinary Shares |
| Biomarin Pharmaceutical In... | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 76.28 per share. | 05 Mar 2021 | 5,000 | 42,840 (0%) | 0% | 76.3 | 381,400 | Common Stock |
| Biomarin Pharmaceutical In... | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 05 Mar 2021 | 5,000 | 47,840 (0%) | 0% | 26.5 | 132,450 | Common Stock |
| Biomarin Pharmaceutical In... | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Mar 2021 | 5,000 | 0 | - | - | Stock Option (Right to buy Common Stock) | |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 2,155 | 2,155 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2021 | 1,475 | 5,731 (0%) | 0% | 0 | Common Stock | |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2020 | 10,900 | 0 | - | - | Non Qualified Stock Option (right to buy) | |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.84 per share. | 14 Dec 2020 | 10,900 | 15,156 (0%) | 0% | 16.8 | 183,556 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 247.62 per share. | 14 Dec 2020 | 1,997 | 5,364 (0%) | 0% | 247.6 | 494,502 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 243.34 per share. | 14 Dec 2020 | 1,815 | 12,105 (0%) | 0% | 243.3 | 441,671 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 246.73 per share. | 14 Dec 2020 | 1,807 | 7,361 (0%) | 0% | 246.7 | 445,834 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 244.45 per share. | 14 Dec 2020 | 1,653 | 10,452 (0%) | 0% | 244.5 | 404,083 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 245.11 per share. | 14 Dec 2020 | 1,284 | 9,168 (0%) | 0% | 245.1 | 314,725 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 248.55 per share. | 14 Dec 2020 | 1,019 | 4,345 (0%) | 0% | 248.5 | 253,269 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 242.29 per share. | 14 Dec 2020 | 857 | 13,920 (0%) | 0% | 242.3 | 207,641 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 241.22 per share. | 14 Dec 2020 | 379 | 14,777 (0%) | 0% | 241.2 | 91,422 | Common Stock |
| Mirati Therapeutics Inc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 249.42 per share. | 14 Dec 2020 | 89 | 4,256 (0%) | 0% | 249.4 | 22,198 | Common Stock |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 73.35 per share. | 05 Aug 2020 | 1,755 | 0 (0%) | 0% | 73.3 | 128,729 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2020 | 1,755 | 0 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 05 Aug 2020 | 1,755 | 1,755 (0%) | 0% | 3.9 | 6,932 | Ordinary Shares |
| Biomarin Pharmaceutical In... | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Aug 2020 | 2,500 | 5,000 | - | - | Stock Option (Right to buy Common Stock) | |
| Biomarin Pharmaceutical In... | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 120.35 per share. | 03 Aug 2020 | 2,500 | 42,840 (0%) | 0% | 120.4 | 300,875 | Common Stock |
| Biomarin Pharmaceutical In... | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.49 per share. | 03 Aug 2020 | 2,500 | 45,340 (0%) | 0% | 26.5 | 66,225 | Common Stock |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 22 Jul 2020 | 1,755 | 1,755 (0%) | 0% | 3.9 | 6,932 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2020 | 1,755 | 1,755 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 60.00 per share. | 22 Jul 2020 | 1,755 | 0 (0%) | 0% | 60 | 105,300 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 25 Jun 2020 | 1,755 | 1,755 (0%) | 0% | 3.9 | 6,932 | Ordinary Shares |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jun 2020 | 1,755 | 3,510 | - | - | Stock Option (Right to Buy) | |
| Horizon Therapeutics Plc | Michael G. Grey | Director | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 25 Jun 2020 | 1,755 | 0 (0%) | 0% | 55 | 96,525 | Ordinary Shares |
| Biomarin Pharmaceutical In... | Michael G. Grey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 May 2020 | 4,300 | 42,840 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges